

The second pX product p27^{x-III} of HTLV-1 is required for gag gene expression

Jun-ichiro Inoue, Motoharu Seiki and Mitsuaki Yoshida*

Laboratory of Viral Oncology, Cancer Institute Kami-Ikebukuro, Toshima-ku, Tokyo 170, Japan

Received 20 October 1986

The human T-cell leukemia virus type-1 (HTLV-1) contains a unique pX region, which encodes the gene products p40^x, p27^{x-III} and p21^{x-III}. p40^x is required for transcriptional trans-activation, whereas p27^{x-III} and p21^{x-III} have no such function. Transfection of pX expression plasmids containing different combinations for the three gene products into cells integrated with HTLV-1 proviruses defective in pX expression revealed that both p40^x and p27^{x-III} are required for expression of the gag protein and accumulation of gag mRNA. These observations suggest that the pX product p40^x activates transcription and p27^{x-III} controls the level of gag mRNA by post-transcriptional modulation.

pX gene HTLV-1 Gene product Gene expression Post-transcriptional regulation

1. INTRODUCTION

Human T-cell leukemia virus type 1 (HTLV-1) [1,2] is thought to be involved in leukemogenesis in adult T-cell leukemia (ATL) [2–5]. The unique pX region between the *env* and 3' LTR of HTLV-1 [6] codes for three proteins, p40^x [7–10], p27^{x-III} and p21^{x-III} [11], and one of these, p40^x also termed *tat-1*, was shown to be a transcriptional trans-activator which can activate the viral long terminal repeat (LTR) [12–18] as well as the genes for interleukin 2 (IL-2) and its receptor (IL-2R) in T cells [19,20]. Thus, p40^x is believed to be essential for efficient viral replication and induction of abnormal proliferation of infected T-lymphocytes. The other two gene products, p27^{x-III} and p21^{x-III} are not required for the trans-activation of the LTR-CAT construction [16–18], IL-2 or IL-2R genes [20] and their roles have not been well elucidated to date. In this work, we found that p27^{x-III} along with p40^x is required for expression of the gag gene from the integrated proviral genome.

* To whom correspondence should be addressed

2. MATERIALS AND METHODS

2.1. Transfection

FL45 cells (6×10^5) were seeded on 60 mm plate and transfected the following day with 6 μ g of plasmid DNA by the calcium phosphate method described [13]. After 40 h incubation, the cells were divided into two groups and subjected to either indirect immunofluorescence staining or to extraction of RNA and proteins.

2.2. RNA and protein analyses

Total cellular RNA was extracted with vanadyl complexes by the procedure of Berger and Birkenmeier [21]. The poly(A) RNA was denatured with 2.2 M formaldehyde, electrophoresed in 1% agarose gel, and transferred onto nitrocellulose filter. RNA on the filter was hybridized with the ³²P-labeled gag probe (see fig.1A) at 42°C under the conditions of 50% formamide and 0.6 M NaCl.

Viral antigens were characterized by blot procedure using serum from an ATL patient.

3. RESULTS

Since the second and third products of the pX region of HTLV-1, p27^{x-III} and p21^{x-III}, were not required for trans-activation of the LTR-CAT [17,18], cellular IL-2 and IL-2R genes [20], we tested the effect of the pX proteins on the expression of genes in the HTLV provirus. A defective provirus genome HTLV_{GAGPX} was constructed by a deletion of the sequence between the *Bgl*III site located at the 5'-region of *pol* and the *Bam*HI site at the 3'-region of *env* of the λ ATK-1 clone (fig.1A) [6]. This defective provirus, HTLV_{GAGPX}, has the capacity to produce the gag proteins and

the smallest pX protein p21^{x-III}, but not the two other major pX proteins p40^x and p27^{x-III} nor *pol* and *env* proteins, since the initiation codons for expression of p40^x and p27^{x-III} were deleted (fig.1A).

HTLV_{GAGPX} DNA along with a gene conferring neomycin resistance was transfected into FL cells, a human amnion cell line, and a stable cell line FL45 was isolated by G418 selection. Southern blot analysis of FL45 DNA showed multicopy integration of HTLV_{GAGPX} (not shown). Neither viral mRNA nor proteins were detected in the FL45 cells by Northern blot analysis, indirect immunofluorescence staining or Western blot analysis (not shown).

The FL45 cell line was transfected with a plasmid, pMTCXdb [20], containing the wild type coding sequence for the pX proteins, the transcription of which is controlled by a metallothionein promoter (fig.1B). After 2 days, the transfected cells were stained by the indirect immunofluorescence method using monoclonal antibody against a gag protein p19. Several percent of transfected cells were stained strongly, indicating production of gag proteins. The gag protein expressed was characterized by Western blot assay. As shown in fig.2A (lane a), a gag precursor Pr53 was detected in cells transfected with pMTCXdb. These results clearly demonstrate that a proviral genome defective in pX expression can express its *gag* gene when the pX functions are supplied exogenously. Transfection with a plasmid, pMTCXss, containing a single large deletion in the coding sequence for p40^x yielded no expression of the gag gene lending support to the conclusion that p40^x trans-activation is required for gag expression.

On the other hand, a mutant plasmid pMTCXds-ATG1&4 [20], which can code for p40^x but not for p27^{x-III} and p21^{x-III} (fig.1B), was also found to be unable to induce gag gene expression (fig.2A, lane b). Normal expression of p40^x in these cells was confirmed by the activation of pLTR-CAT and also by Western blot analysis. Failure of p40^x alone to induce gag gene expression was unexpected since this gene product is capable of activating transcription from the viral LTR [16-18]. To verify the requirement of p27^{x-III}/p21^{x-III} for expression of the gag gene, a complementation assay was carried out: two plasmids, pMTCXds-ATG1&4 and pMTCXss,




Fig.1. Schematic illustration of HTLV-1 proviruses, λ ATK-1 and GAGPX (A), and of plasmids for pX expression (B). (A) S.D. and S.A., splicing donor and acceptor sites; (Δ) initiation codons; thick horizontal bar represents DNA sequences used for hybridization probe. (B) Construction of pX plasmids. The cDNA sequence of pX mRNA were inserted under the metallothionein promoter (MT) with various modifications. Details for pMTCXdb and pMTCXds-ATG1&4 were described in [18]. pMTCXss has a large deletion from *Stu*I (no.8033 from the 5'-end of λ ATK-1) to *Sma*I (no.8310). (Δ) Initiation codons.




Fig.2. Effect of p27^{x-III} expression on the levels of gag protein and mRNA. (A) Detection of gag gene products: whole cell lysate (30 μ g proteins) was subjected to 12.5% polyacrylamide gel electrophoresis followed by blotting analysis using an ATL patient serum. Lysates of FL45 cells transfected with 6 μ g of pMTCXdb (a), pMTCXds-ATG1&4 (b), pMTCXds-ATG1&4 plus pMTCXss (c) and pMTCXss (d) were analysed. Lysate of HUT102 cells (e). (B) Detection of the gag mRNA: poly(A) RNA extracted from 3×10^6 cells were analysed by the Northern blot procedure using the gag probe (see fig.1A). RNA samples were prepared from the same cells as described in (A).

which can code for p40^x and p27^{x-III}/p21^{x-III}, respectively, were cotransfected into FL45 cells. Expression of the gag precursor Pr53 was observed (fig.2A, lane c). This result clearly indicates that p40^x alone is not sufficient and a second product, p27^{x-III} or p21^{x-III}, is required for gag gene expression. However, transfection of pMTCXds-ATG1 (p40^x and p21^{x-III}) could not induce the gag expression, thus it was suggested that p27^{x-III} is the required second factor.

To elucidate which process is modulated by p27^{x-III}, gag mRNA in transfected FL45 cells was analysed by the Northern blot procedure using the gag sequence as a probe. In conjunction with the expression of Pr53, two distinct gag mRNA species (5.0 and 9.7 kb) were observed in FL45 cells transfected with the wild type plasmid, but not in cells with plasmid unable to express p27^{x-III} (fig.2, lanes a and b). The 5.0 kb band corresponds to a

transcript from the defective provirus sequence HTLV_{GAGPX}, and the 9.7 kb may represent a transcript from tandemly integrated proviral sequences. Complementation of plasmid lacking in expression of p27^{x-III} with a p27^{x-III} expression plasmid rescued the gag mRNA (fig.2B, lane c). These results clearly indicate that p27^{x-III} plays a critical role in regulation of gag mRNA levels. No gag mRNA was detected without p40^x even in the presence of p27^{x-III} (fig.2B, lane d).

4. DISCUSSION

In this study, we have presented evidence that p27^{x-III}, a second pX protein of HTLV-1, is required for expression of the gag gene and also for accumulation of the mRNA. From these observations, it was concluded that p27^{x-III} affects the mRNA levels. For activation of transcription from the LTR in pLTR-CAT, cellular IL-2 or IL-2R genes, p40^x alone is sufficient [17,18,20]. However, for gag gene expression, both p40^x and p27^{x-III} were found to be required. Since p40^x can activate transcription from the LTR [12-18], even from the integrated form of the LTR (J.I., unpublished), it is reasonable to assume that p27^{x-III} modulates the post-transcriptional process, which eventually affects the gag mRNA levels. The process modulated by p27^{x-III} could be splicing, transport, or stabilization of mRNA precursors or the mRNA itself. A similar requirement for p27^{x-III} was observed on other proviral constructions, thus it should not be an artifact of the HTLV_{GAGPX} construction in particular (not shown).

Post-transcriptional regulation was also demonstrated on HIV (HTLV III/LAV) by Sodroski et al. [22]. They reported, however, that gag and env expression were affected by the *art* gene, but that their mRNA levels were not. Therefore, the mode of function of p27^{x-III} seems to differ from the *art* of HIV.

ACKNOWLEDGEMENTS

This work was supported in part by a Grant-in-Aid for Special Project Research, Cancer-Bioscience from the Ministry of Education, Science and Culture of Japan.

REFERENCES

- [1] Poiesz, B.J., Ruscetti, F.W., Gazdar, A.F., Bunn, P.A., Minnan, J.D. and Gallo, R.C. (1980) *Proc. Natl. Acad. Sci. USA* 77, 7415–7419.
- [2] Yoshida, M., Miyoshi, I. and Hinuma, Y. (1982) *Proc. Natl. Acad. Sci. USA* 79, 2031–2035.
- [3] Hinuma, Y., Nagata, K., Hanaoka, M., Matsumoto, T., Kinoshita, K., Shirakawa, S. and Miyoshi, I. (1981) *Proc. Natl. Acad. Sci. USA* 78, 6476–6480.
- [4] Wong-Staal, F., Hahn, B., Manzari, V., Colonbini, S., Franchini, G., Gelman, E.P. and Gallo, R.C. (1983) *Nature* 302, 626–628.
- [5] Yoshida, M., Seiki, M., Yamaguchi, K. and Takatsuki, K. (1984) *Proc. Natl. Acad. Sci. USA* 81, 2534–2537.
- [6] Seiki, M., Hattori, S., Hirayama, Y. and Yoshida, M. (1983) *Proc. Natl. Acad. Sci. USA* 80, 3618–3622.
- [7] Kiyokawa, T., Seiki, M., Imagawa, K., Shimizu, F. and Yoshida, M. (1984) *Gann* 75, 747–751.
- [8] Lee, T.H., Coligan, J.E., Sodroski, J.G., Haseltine, W.A., Salahuddin, S.A., Wong-Staal, F., Gallo, R.C. and Essex, M. (1984) *Science* 226, 57–61.
- [9] Miwa, M., Shimotohno, K., Hoshino, H., Fujino, M. and Sugimura, T. (1984) *Gann* 75, 752–755.
- [10] Slamon, D.J., Shimotohno, M., Cline, M.J., Golde, D.W. and Chen, I.S.Y. (1984) *Science* 226, 61–65.
- [11] Kiyokawa, T., Seiki, M., Iwashita, S., Imagawa, K., Shimizu, F. and Yoshida, M. (1986) *Proc. Natl. Acad. Sci. USA* 82, 8359–8363.
- [12] Sodroski, J.G., Rosen, G.A. and Haseltine, W.A. (1984) *Science* 225, 375–381.
- [13] Fujisawa, J., Seiki, M., Kiyokawa, T. and Yoshida, M. (1985) *Proc. Natl. Acad. Sci. USA* 82, 227–2281.
- [14] Cann, A.J., Rosenblatt, J.D., Wachsman, W., Shah, N.P. and Chen, I.S.Y. (1985) *Nature* 318, 571–574.
- [15] Felber, B.K., Paskalis, H., Kleiman-Ewing, C., Wong-Staal, F. and Pavlakis, G.N. (1985) *Science* 229, 675–679.
- [16] Sodroski, J.G., Rosen, C.A., Goh, W.C. and Haseltine, W.A. (1985) *Science* 228, 1430–1434.
- [17] Seiki, M., Inoue, J., Takeda, T., Hikikoshi, A., Sato, M. and Yoshida, M. (1985) *Jap. J. Cancer Res.* 76, 1127–1131.
- [18] Seiki, M., Inoue, J., Takeda, T. and Yoshida, M. (1986) *EMBO J.* 5, 561–565.
- [19] Greene, W.C., Leonard, W.J., Wano, Y., Svetlik, P.B., Pepper, N.J., Sodroski, J.G., Rosen, C.A., Goh, W.C. and Haseltine, W.A. (1986) *Science* 232, 877–880.
- [20] Inoue, J., Seiki, M., Taniguchi, T., Tsuru, S. and Yoshida, M. (1986) *EMBO J.*, in press.
- [21] Berger, S.L. and Birkenmeier, C.S. (1979) *Biochemistry* 18, 5143–5149.
- [22] Sodroski, J.G., Goh, W.C., Rosen, C.A., Dayton, A., Terwilliger, E. and Haseltine, W.A. (1986) *Nature* 321, 412–417.